Clarence L.

Nutshell therpeutics decipher undruggable by Allostery. By leveraging AlloStar allosteric drug discovery platform, composed of a powerful and well-integrated set of computational modules and experimental tools based on in-house proprietary AI algorithm and deep know-how derived from biochemistry and biophysics, possesses the unique capability of discover a host of drug entities including various types of protein activators, subtype/mutation selective small molecules, regulatory molecules of protein-protein interaction and stabilizer of intrinsically disordered proteins. Coordinate with the Founder on both in-house asset progression and platform collaborations to advance drug discovery and development.

Xgene Pharmaceutical Inc. develops high-impact medications to address unmet and underserved needs in neurological conditions. Its leading asset, XG005, a non-opioid, dual-targeting analgesic, has successfully completed a U.S. Phase IIb/III trial for acute pain in bunionectomy and a China Phase II trial for osteoarthritis. Coordinated cross-functional teams to close an exclusive Phase III asset license with a key Chinese biopharma partner. Drive strategic out-licensing and relationship management for two late-stage assets currently under negotiation with global biopharma. Collaborate with the CEO to lead the Series C+ and D funding process, managing complex financial modeling, due diligence, and term sheet negotiations.

Hengxu Capital is a leading China-based private equity firm backed by SAIC Motor. The firm currently manages three funds with over 40 billion RMB in assets under management (AUM). I focused on biotech and unmet medical needs-driven healthcare investments. My responsibilities spanned the entire investment lifecycle, including deal sourcing, analysis, negotiation, due diligence, execution, and portfolio management. Key investments include Asieris Therapeutics, UTC Therapeutics, HIFIBIO Therapeutics, Xgene Pharmaceutical, Axter Therapeutics, Cytosinlab Therapeutics, and Nutshell Therapeutics.

Viva Biotech (1873.HK) operates a leading, one-stop platform for global biopharmaceutical innovation, integrating top-tier CRO/CDMO services with a unique investment approach. As the corporate venture arm, Viva BioInnovator (VBI) is dedicated to identifying and investing globally in early-stage biotech companies focusing on unmet medical needs. VBI utilizes its proprietary Equity-for-Service (EFS) model, which provides portfolio companies with essential capital and R&D services, leveraging Viva's world-leading Structure-Based Drug Discovery (SBDD) platform to accelerate drug candidates from discovery to clinic. I lead strategic biotech investments for VBI, including the successful investment in Regenacy Pharmaceuticals. My role spans the full deal lifecycle, from comprehensive origination and rigorous EFS opportunity evaluation to due diligence and execution.

Amphora Capital, a prominent Beijing-based private equity and venture capital firm established in 2006, managing over CNY 20 billion in assets. The firm specializes in early and growth-stage investments across strategic sectors, including Biotechnology and TMT, adhering to a philosophy of "trend analysis and value investment." A core part of our strategy involves identifying attractive segments within the healthcare industry by analyzing macro trends and leveraging in-depth market research to find companies with strong growth potential. I was responsible for the firm's biotech deal flow, from market trend analysis and segment identification to rigorous prospective investment evaluation. I led investments in key therapeutic companies, including BreStem Therapeutics and Xollent Therapeutics, overseeing all deal negotiation and execution.